]>
IRCT20171230038142N12 IRCT 2020-02-23 Esfahan University of Medical Sciences Evaluating the effect of nebulizing colistine with nebulizing colistin-fosfomycin in comparison to nebulizing colistine in Ventillator-Associated Pneumonia with multidrug-resistant Acinetobacter Baumanii in Alzahra Intensive Care Units Evaluating the effect of nebulizing colistine with nebulizing colistin-fosfomycin in comparison to nebulizing colistine in Ventillator-Associated Pneumonia with multidrug-resistant Acinetobacter Baumanii in Alzahra Intensive Care Units 2019-08-23 anticipated 78 Complete https://irct.ir/trial/45813 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will first be selected by convenience sampling from the ICU ward of Alzahra Hospital in Isfahan. They will then be randomly divided into two groups using binary replacement blocks, Blinding description: Patients are admitted to the ICU and are unaware of the course of treatment of other treatment groups and are only aware of their treatment, and the analyzer does not know the patients and the treatment content. 2-3 Ventillator-Associated Pneumonia. Intervention 1: Intervention group: The first group is treated with inhaled Colistin, along with meropenem and intravenous Colistin. The study included 39 patients with ventilator pneumonia whose response to culturing of their secretions was strongly resistant to Acinetobacter baumannii. Intervention may be termination of fever, reduction of lung discharge or radiographic changes. Intervention 2: Intervention group:The second group is treated with inhaled Colistin-fosfomycin in combination with intravenous meropenem and Colistin. The study included 39 patients with ventilator pneumonia whose response to culturing of their secretions was strongly resistant to Acinetobacter baumannii. Intervention may be termination of fever, reduction of lung discharge or radiographic changes. Yes - There is a plan to make this available What will be shared: Two years after the results are shared. When: Two years after the results are shared. To whom: Doctors and Infectious Diseases Conditions: Comparison of the new treatment with the present one Where to obtain: Send an email to a.hakamifard@med.mui.ac.ir How to obtain: Send an email to a.hakamifard@med.mui.ac.ir Comments:
public Atusa Hakami Fafd
Al-Zahra Hospital, Sofah Boulevard.
Esfahan Iran (Islamic Republic of) 81746-73461 +98 31 3668 0048 a.hakamifard@med.mui.ac.ir Esfahan University of Medical Sciences scientific Atusa Hakami Fafd
Al-Zahra Hospital, Sofah Boulevard.
Esfahan Iran (Islamic Republic of) 81746-73461 +98 31 3668 0048 a.hakamifard@med.mui.ac.ir Esfahan University of Medical Sciences Iran (Islamic Republic of) Patient hospitalization in ICU Age between 20 and 85 Diagnosis of ventilator pneumonia for the patient Diagnosis of colistin sensetive Acinetobacter baumannii Patient satisfaction 20 years 85 years Both Diagnosis Another concomitant disease The patient died before the response Start treatment of acinetobacter J95.851 Ventilator associated pneumonia Treatment - Drugs Treatment - Drugs Intervention group: The first group is treated with inhaled Colistin, along with meropenem and intravenous Colistin. The study included 39 patients with ventilator pneumonia whose response to culturing of their secretions was strongly resistant to Acinetobacter baumannii. Intervention may be termination of fever, reduction of lung discharge or radiographic changes. Intervention group:The second group is treated with inhaled Colistin-fosfomycin in combination with intravenous meropenem and Colistin. The study included 39 patients with ventilator pneumonia whose response to culturing of their secretions was strongly resistant to Acinetobacter baumannii. Intervention may be termination of fever, reduction of lung discharge or radiographic changes. Duration of treatment. Timepoint: Upon completion of treatment and response to treatment. Method of measurement: Counting the days of hospitalization and receiving treatment until the response arrives. Illness severity. Timepoint: Before and after taking the drug. Method of measurement: Based on CPIS criteria. Response to treatment. Timepoint: Before and after taking the drug. Method of measurement: Based on microbial eradication criteria. Esfahan University of Medical Sciences Approved 2019-06-02 Ethics Committee of Isfahan University of Medical Sciences Isfahan University of Medical Sciences, Hezar Jarib Ave. Isfahan Isfehan Iran (Islamic Republic of)